Literature DB >> 2434015

Surgical procedures for ovarian cancer.

J H Shepherd, M E Crowther, B G Ward, P Singh.   

Abstract

The management of 191 patients with ovarian cancer is presented. A significant proportion of these patients were initially seen (16%) or operated on (7%) by a general surgeon. The current surgical approach to this disease should be aggressive, and in 23% of these patients a non-gynaecological surgical procedure was required. Although chemotherapy is the main form of treatment following surgery, its chances of success are influenced by the amount of tumour left after surgery. The picture is not uniformly hopeless, and of 34 patients who subsequently underwent laparotomy to check the effectiveness of chemotherapy, 10 (29%) had no evidence of disease. Palliative surgery also has an important place in the management of this disease to provide comfort from disabling symptoms, and in some cases it may prolong life.

Entities:  

Mesh:

Year:  1986        PMID: 2434015      PMCID: PMC2498298     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  6 in total

Review 1.  Management of ovarian carcinoma. Current concepts and future prospects (first of two parts).

Authors:  J S Tobias; C T Griffiths
Journal:  N Engl J Med       Date:  1976-04-08       Impact factor: 91.245

2.  The role of cytoreductive surgery in advanced carcinoma of the ovary: an analysis of primary and second surgery.

Authors:  E Wiltshaw; K S Raju; I Dawson
Journal:  Br J Obstet Gynaecol       Date:  1985-05

3.  Primary cytoreductive surgery for epithelial ovarian cancer.

Authors:  N F Hacker; J S Berek; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-04       Impact factor: 7.661

4.  Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.

Authors:  C T Griffiths; L M Parker; A F Fuller
Journal:  Cancer Treat Rep       Date:  1979-02

5.  Radioimmunodiagnosis of ovarian cancer using 123I-labelled, tumor-associated monoclonal antibodies.

Authors:  A A Epenetos; J Shepherd; K E Britton; L Hawkins; C C Nimmon; J Taylor-Papadimitriou; H Durbin; J S Malpas; S Mather; M Granowska
Journal:  Cancer Detect Prev       Date:  1984

6.  Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute.

Authors:  J P Smith; T G Day
Journal:  Am J Obstet Gynecol       Date:  1979-12-01       Impact factor: 8.661

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.